BioTime Provides Financial Information about Its Acquisition of ES Cell International Pte Ltd.

ALAMEDA, Calif.--(BUSINESS WIRE)--On Friday, July 16, 2010 BioTime, Inc. (NYSE Amex: BTIM) filed an amendment to its Current Report on Form 8-K with the Securities and Exchange Commission reporting BioTime’s acquisition of ES Cell International Pte Ltd, a Singapore private limited company (“ESI”). BioTime filed the amendment in the time frame provided in the SEC’s rules to include audited financial statements of ESI and pro forma financial statements showing the effect of the acquisition of ESI on BioTime’s financial statements. The ESI financial statements are stated in Singapore dollars rather than U.S. dollars and were prepared under Singapore accounting principles and audited under U.S auditing standards. The pro forma financial statements are presented in U.S. dollars.